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(lowest vs highest; HR 1.12, 95%CI 1.07-1.16), grade (high vs low, HR 1.72, 95%CI 
1.63-1.82), tumour size (2-5 cm vs 1-2 cm; HR 1.46, 95%CI 1.40-1.51), and a higher 
number of positive lymph nodes (1-3 vs 0; HR 1.40, 95%CI 1.34-1.46 and > 10 vs 0; HR 
3.19, 95%CI 3.00-3.39) influenced death, all to a larger extent than surgical volume 
did. ConClusions: In the Netherlands, surgical hospital volume influences 10-year 
overall survival only marginally, and far less than patient and tumour characteris-
tics. No difference in survival was revealed for invasive non-metastatic breast cancer 
patients in hospitals with 75-99 operations per year compared with hospitals with 
over 200 operations per year.
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objeCtives: For patients with relapsed or refractory (R/R) mantle cell lymphoma 
(MCL), prognosis is poor, with a median survival of one to two years, and treat-
ment options are very limited. In a recent phase II trial (PCYCY-1104), Ibrutinib 
(Imbruvica™), a first-in-class oral once a day covalent Bruton’s tyrosine kinase 
inhibitor, was associated with a median progression-free survival (PFS) of 13.9 
months. After a median follow-up of 15.3 months, 63% of patients were alive. 
The aim of the current study was to evaluate the projected life years (LYs) and 
quality-adjusted LYs (QALYs) associated with ibrutinib and other treatments for 
R/R MCL. Methods: Patients with R/R MCL were simulated to receive treatment 
in a health state, survival partition model. Patients received ibrutinib, bendamus-
tine and rituximab (BR), fludarabine, mitoxantrone, and cyclophosphamide (FMC), 
temsirolimus, or other comparators until death or until progression of disease, 
at which point they were modeled to receive a subsequent line of treatment or 
best supportive care. Clinical inputs for ibrutinib were informed by PCYC-1104 
trial data; OS was extrapolated to estimate survival outcomes. Clinical inputs for 
comparators were informed by published sources identified through a systematic 
literature review. Utility values were informed by published studies. Outcomes 
were discounted by 3.5%. Results: Treatment with ibrutinib resulted in better 
health outcomes, incrementally increasing overall LYs by 0.92, 0.86, and 0.92 and 
PFS LYs by 0.87, 0.87, and 0.87 compared to BR, FMC, and temsirolimus, respec-
tively. Ibrutinib was associated with 0.71, 0.70, and 0.72 overall incremental QALYs 
compared to BR, FMC, and temsirolimus, respectively. ConClusions: Compared 
with other therapies, Ibrutinib yielded an average incremental benefit of 0.90 LYs 
for R/R MCL patients, largely driven by the significant incremental improvement 
in duration of PFS. Currently a phase III trial is ongoing, the data from which will 
be used to validate the model.
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objeCtives: This study was aimed at evaluating the overall survival (OS) gains 
associated with HER-2 directed therapies in patients with metastatic breast 
cancer. Methods: A bibliographic search was conducted in the MEDLINE (PubMed) 
and in the Cochrane Central Register of Controlled Trials databases, from their 
inception through March, 2014. Only phase III clinical trials (RCTs) including 
HER2-positive metastatic breast cancer patients have been included in this review, 
irrespective of the treatment administered (i.e., chemotherapy and/or hormone 
therapy, chemotherapy and/or hormone therapy plus HER2-targeted therapy). OS 
was defined as time from randomisation until the occurrence of death from any 
cause. Studies have been grouped according to the line of treatment, i.e. first-line 
or second-line or beyond. Results: Seventeen RCTs were eligible for inclusion, of 
which 12 assessed therapies targeting metastatic breast cancer HER2+ in the first 
line setting. OS improved from 20.3 months in the first RCT (standard chemotherapy; 
Slamon et al, 2001) evaluating HER-2 targeting therapies to 48 months (estimated 
median OS) in the study of Swain and colleagues (2013), with triple combination 
of pertuzumab, trastuzumab and docetaxel. Four studies evaluated OS of HER-2 
targeting therapies in second-line setting of metastatic breast cancer. The OS in 
second-line setting improved from 15.3 months (capecitabine; Cameron et al, 2008) 
to 30.7 months (trastuzumab emtancine; Verma et al, 2012). In the third-line setting, 
the association of lapatinib + trastuzumab has demonstrated to improve OS in 4.5 
months compared with lapatinib alone (14 months vs 9.5 months; Blackwell et al, 
2012). ConClusions: The HER-2 directed therapies had an undeniable benefic 
impact in the overall survival of patients with HER-2 positive metastatic breast 
cancer. Triple combination of docetaxel, pertuzumab and trastuzumab is associated 
with a survival extent of more than 3.5 years, compared with a life expectancy of 
1,5 years achieved 13 years ago.
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objeCtives: Treatment options for chronic lymphocytic leukemia (CLL) who 
received prior therapy are limited; no standard of care exists. In a recent phase 
III clinical trial (PCYC-1112), ibrutinib, an oral, once-a-day, first-in-class covalent 
Bruton’s tyrosine kinase inhibitor, was associated with improved progression-free 
survival (PFS, HR= 0.215) and overall survival (OS, HR= 0.387) compared with ofa-
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objeCtives: The association between the disease-free interval (DFI) and survival 
after a locoregional recurrence (LRR) or second primary (SP) breast cancer remains 
uncertain. The objective of this study is to clarify this association to obtain more 
information on expected prognosis. Methods: Women first diagnosed with early 
breast cancer between 2003-2006 were selected from the Netherlands Cancer 
Registry. LRRs and SP tumours within five years of first diagnosis were examined. 
The five-year period was subsequently divided into three equal intervals. Prognostic 
significance of the DFI on survival after a LRR or SP tumour was determined using 
Kaplan-Meier estimates and multivariable Cox regression analysis. Follow-up was 
complete until January 1,2013. Results: A total of 36,255 women was included in 
the analysis. LRRs or SP tumours were diagnosed in 1,646 (4.5%) patients: 55% devel-
oped a LRR and 45% SP breast cancer. Longer DFI was strongly and independently 
related to an improved survival after a LRR (long versus short: HR 0.63, 95% CI 0.46-
0.86; medium versus short HR 0.80, 95% CI 0.64-1.00; P for trend 0.01). Other factors 
related to improved survival after LRR were younger age (< 70 years) and surgical 
removal of the recurrence. No significant association was found between DFI and 
survival after SP tumours. ConClusions: This is the first study to explore the asso-
ciation between the DFI and survival after recurrence in a nationwide population-
based cancer registry. The DFI before a LRR is an independent prognostic factor for 
survival, with a longer DFI predicting better prognosis.
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objeCtives: Overall survival (OS) data from clinical trials in oncology are often 
incomplete, thus modelling over the lifetime horizon requires long term extrapola-
tion and it is a critical input to cost-effectiveness studies. Data from the Surveillance, 
Epidemiology, and End Results (SEER) program may provide good validation on the 
long term OS. The objective was to examine the parametric functions that best 
fit data in lung cancer (LC) of various histologies in SEER. Methods: SEER data 
(2004-2011) were analyzed for patients diagnosed with stage IV small cell, large cell, 
squamous cell carcinoma and adenocarcinoma of the lung with complete follow-
up. Mean age was 68.03 (sd 11.67) and 55.5% were males, with varying baseline age 
and gender distribution by histology. Treatment status could not be established. 
Parametric models for OS were fitted using exponential, Gompertz, loglogistic, log-
normal, and Weibull distributions. Models were fitted with and without covariates. 
Fits were inspected and compared graphically using survival and quantile-quantile 
plots, and statistically using the Akaike Information Criterion (AIC). Modelled mean 
life expectancy results were compared to the restricted mean life expectancy of 
the Kaplan-Meier estimator. Results: The lognormal distribution was found to 
have the best fit within the SEER population, both with and without covariates 
indicating that a small proportion of patients survive for a long time despite the 
poor general prognosis of any type of LC. Loglogistic and gamma distributions were 
2nd and 3rd best, followed by Weibull, Gompertz and exponential, for all histolo-
gies. The last three fitted the data poorly, and underestimated mean life expec-
tancy. ConClusions: Only small proportions of LC patients are alive at 5-8 years, 
nevertheless the mean OS estimates are impacted by the choice of survival function. 
The lognormal distribution fit best across all histologies indicating a higher propo-
tion of patients alive than estimated with Weibull models.
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objeCtives: For low-volume tumours, high surgical hospital volume is associated 
with better survival. For high volume tumours like breast cancer this association 
is unclear. The aim of this study is to determine to what extent the yearly surgi-
cal hospital breast cancer volume is associated with overall survival. Methods: 
All patients, diagnosed with primary invasive non-metastatic breast cancer in the 
period 2001-2005, were selected from the Netherlands Cancer Registry. Hospitals 
were grouped by their annual volume of surgery for invasive breast cancer. Cox 
proportional hazard models were used including patient and tumour characteris-
tics as covariates. Follow-up was completed until the 1thof February 2013. Primary 
endpoint was 10-year overall survival rate. Results: In total 58,982 patients with 
invasive non-metastatic breast cancer were diagnosed during the period 2001-2005. 
Hospitals were grouped by their (mean) annually surgical volume: < 75 (n= 19), 75-99 
(n= 30), 100-149 (n= 29), 150-199 (n= 9) and ≥ 200 (n= 14). The 10-year observed survival 
rates were 77%, 81%, 80%, 82% and 82%, respectively. After case-mix adjustment 
patients in low volume hospitals had a HR of 1.08 (< 75 vs ≥ 200; 95%CI 1.02-1.14). 
Age at diagnosis (continuous, HR 1.05, 95%CI 1.05-1.05), socioeconomic status 
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objeCtives: To allow budgeting of pharmaceutical expenditure for cancer drugs 
in Germany, we forecasted future outpatient pharmaceutical expenditure for 
cancer treatment from the perspective of the statutory health insurance (SHI) for 
2016. Methods: Based on data of the Techniker Krankenkasse (TK), a large German 
sickness fund with more than 8.2 million insured, we forecasted pharmaceutical 
expenditure for 12 cancer indications in 2016 (according to ICD-10: C16, C18-21, 
C22, C26.9/C49.9, C34, C43, C50, C56, C61, C73, C90, C91.1). To extrapolate results 
to whole SHI, we adjusted for differences in demographics of insured between 
TK and SHI using publicly available data, i.e. KM6 statistics. We also incorporated 
trends in membership to SHI. To assess the impact of new drugs, we obtained expert 
opinion by IMS Health on (a) the timing of drug launches in the German cancer 
market, (b) the expected prices of new drugs and (c) the extent to that new drugs will 
replace existing pharmaceuticals. For calculations, we assumed that newly launched 
drugs will reach on average a diffusion of 20% of their market potential until 
2016. Results: According to our model, SHI outpatient pharmaceutical expendi-
ture for these 12 cancer indications was million € 2,780 in 2012, i.e., 9.5% of total 
outpatient pharmaceutical expenditure. In 2016, we expect annual pharmaceutical 
expenditure for these indications to increase by 17.2% to million € 3,258. Of the 26 
new drugs identified to be launched until 2016,10 will at least partly replace existing 
pharmaceutical treatments. Thus, million € 526 of our budget estimate will be due to 
new drugs, € 2,650 million will be due to pharmaceuticals that were already launched 
in 2012 while € 82 million will be due to demographic change. ConClusions: The 
expected increase in costs for cancer drugs are a financial challenge for German 
SHI. Whether benefit of new drugs and expected costs can be considered fair value 
needs to be investigated elsewhere.
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objeCtives: To determine the budget impact of everolimus (in combination with 
letrozole/anastrozole) as a second-line treatment for ER+ HER2-negative advanced 
and metastatic breast cancer in postmenopausal women in Kazakhstan. Methods: 
A cumulative cohort model was developed to estimate the five-year costs associated 
with introducing everolimus to the Kazakh health care system, with two scenarios: 
“with everolimus” and “without everolimus”. Treatment-specific PFS and OS data 
were extrapolated from trial data using a Weibull function. It was assumed that 
data from the BOLERO-2 trial (everolimus+exemestane vs exemestane alone) were 
representative of everolimus+letrozole/anastrozole and letrozole/anastrozole used 
in the model. Per-patient drug, health state, adverse event costs were calculated. 
The per-patient costs were multiplied by the number of patients expected to receive 
each treatment according to predicted market share, which was split between 
everolimus+letrozole/anastrozole, letrozole/anastrozole alone, chemotherapy and 
tamoxifen. Results: The within-trial data from BOLERO-2 reported 17 month OS 
of 74.7% and 67.6% for everolimus+exemestane and exemestane alone, respectively. 
The utilities reported in BOLERO-2 (data available up to week 78) were 0.67 and 
0.70 for everolimus+exemestane and exemestane alone, respectively. The five year 
results demonstrate that the introduction of everolimus leads to a 12% increase in 
drug costs, a 2% reduction in pre-progression health state costs, a 1% increase in 
post-progression health state costs and a 2% reduction in adverse event costs. The 
net result is a 2% increase in total costs, from T16.97 billion to T17.389 billion over a 
period of five years. ConClusions: The analysis estimated that, if everolimus were 
to be introduced to the Kazakh health care market for the treatment of ER+ HER2- 
advanced breast cancer, there would be a small impact upon overall health care 
expenditure. An increase in drug acquisitions costs was largely offset by a reduction 
in other health care costs due to improved disease management.
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objeCtives: To assess the impact of genotyping acute myeloid leukemia (AML) 
patients for CYP2C19*17 gene variant status prior to induction-consolidation therapy 
from the perspective of a United States (U. S.) payer. Methods: Developed to aid 
U. S. payers regarding the budgetary impact of DNA genotyping, this model exam-
ines the predicted economic outcomes of a hypothetical cohort of 100 neutropenic 
AML patients under two alternatives: (1) standard voriconazole prophylaxis and (2) 
genotyping patients for targeted prophylaxis. Published allelic frequencies estimate 
27% of the general population may have at least one *17 allele. The presence of the 
CYP2C19*17 allele results in more rapid metabolism and clearance of voriconazole, 
which can lead to underdosing and ineffective prophylaxis on the standard regi-
men. The incidence of invasive fungal infection is 15% without effective prophylaxis 
and is reduced to 6.6% upon adequate prophylaxis. Targeted prophylaxis based on 
genotyping prescribes an alternative drug or higher voriconazole dose in patients 
with the *17 allele. Further model parameters were taken from published litera-
ture and 2014 CMS Laboratory Fee Schedule. Results: The average total cost of 
care for AML patients receiving standard versus targeted voriconazole prophylaxis 
was $46,795 and $46,385 per patient, respectively. In addition to the $410 saved 
per patient, the number of invasive fungal infections was reduced from 6.6 to 4.3 
tumumab. The current study aimed to evaluate the projected life years (LYs) and 
quality-adjusted LYs (QALYs) associated with ibrutinib, ofatumumab, and other 
therapies for treatment of CLL with prior therapy. Methods: A health state model 
simulated treatment of a cohort of CLL patients who had received prior therapy. 
Patients were simulated to receive either ibrutinib or ofatumumab until death or 
disease progression, at which point they received subsequent treatment or best 
supportive care. Clinical inputs for ibrutinib and ofatumumab were informed by 
PCYC-1112 trial data (N= 391). Long-term follow-up data from PCYC-1102 and PCYC-
1103 trials (combined N= 101) was used in sensitivity analysis. Long-term OS and PFS 
were extrapolated from clinical trials to estimate survival outcomes. Utility were 
informed by published studies. Evaluation of ibrutinib versus other existing agent 
and emerging agents including idelalisib and ABT-199 was included in a sensitivity 
analysis. Long-term health outcomes were discounted by 3.5%. Results: Treatment 
with ibrutinib resulted in better health outcomes, incrementally increasing LYs 
by 0.63 and progression-free LY by 0.87 over a 5-year time horizon compared to 
ofatumumab, which lead to 0.47 incremental QALYs. In a 10 year time horizon 
analysis, ibrutinib increased LYs by 0.79. Ibrutinib was also associated with increased 
LYs and QALYs compared to other existing and emerging treatments. The model 
results are most sensitive to the approaches used to extrapolate OS. ConClusions: 
Ibrutinib was demonstrated to yield better health outcomes for CLL patients with 
prior therapy compared to ofatumumab, largely driven by significant improvements 
in PFS and OS.
CaNCer – Cost Studies
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objeCtives: To estimate the budget impact resulting from the introduction of 
aflibercept for the treatment of metastatic colorectal cancer (mCRC) within drug 
program in Poland. Methods: Analysis was performed in 3-year time horizon 
(2014-2016) from the public payer (NHF) perspective. Target population is defined as 
adult patients with mCRC that is resistant to or has progressed after an oxaliplatin-
containing regimen (including patients who experienced distant relapse within 
6 months of completion of oxaliplatin-based adjuvant therapy). Eligible patient 
population was estimated by compilation of following data: epidemiological studies, 
local market study, IMS data, survey among Polish oncologists. Market shares of dif-
ferent regimens (aflibercept 4 mg/kg +FOLFIRI, bevacizumab 10 mg/kg +FOLFOX-4, 
FOLFIRI) were projected based on the NHF data and experts’ opinion. Following cost 
categories were included: drug acquisition and administration (anti-VEGF, chemo-
therapy), diagnostics, monitoring and adverse events (grade 3-4). Results: With the 
introduction of aflibercept, estimated annual number of patients starting aflibercept 
treatment will be 90, 209 and 224 in year 2014, 2015 and 2016, respectively. Total 
annual expenditures in year 2014, 2015 and 2016 were calculated to be 39.3, 40.3 and 
41.2 million PLN in scenario without aflibercept, compared with 37.4, 34.9 and 35.0 
million PLN, respectively, with the introduction of aflibercept. In case of aflibercept 
reimbursement, the NHF would save 1.9 million PLN in year 2014, 5.3 million PLN 
in year 2015 and 6.1 million PLN in year 2016. ConClusions: The introduction of 
aflibercept would result in savings for the NHF in Poland, mainly as a consequence 
of reduced pharmacological costs compared to bevacizumab.
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objeCtives: Sorafenib, a multikinase inhibitor, received Food and Drug 
Administration (FDA) -approval in 2013 for treatment of patients with locally 
recurrent or metastatic, progressive, radioactive iodine-refractory (RAI-r) dif-
ferentiated thyroid carcinoma (DTC). A budget impact model (BIM) was devel-
oped from a United States (US) payer perspective to estimate the costs of adding 
sorafenib to the set of available treatments in a hypothetical health plan in the 
RAI-r DTC population. Methods: An Excel-based BIM evaluated costs of RAI-r 
DTC with other FDA-approved and compendia-recommended treatments using 
baseline and projected market shares. Clinical inputs included the prevalence of 
RAI-r, average monthly dosage, and average duration of sorafenib and other FDA-
approved and compendia-recommended treatments. Economic inputs for each 
treatment included the wholesale acquisition cost (WAC) per dose and hospital 
administration costs per month. A net per-month cost to the payer for sorafenib 
was $6,872. Laboratory testing costs were derived from product-specific package 
inserts and the Centers for Medicare & Medicaid Services (CMS) Physician Fee 
Schedule. Sorafenib market share was assumed to increase from 35% at baseline 
to 54% at 1 year, with shift from other treatments coming mostly (12%) from 
clinical trial/no treatment. The duration of sorafenib treatment was 11 months 
based the DECISION trial. Results: An estimated 25 patients with RAI-r DTC 
were eligible for treatment with sorafenib. Costs increased 25% ($282,467) or $0.02 
per member per month (PMPM) from baseline to 1 year post baseline. Sensitivity 
analyses, varying default inputs for duration of treatment (±2 months) and esti-
mated market share for sorafenib (±10%), showed greatest sensitivity to sorafenib 
market share (incremental total costs: $180,812–$384,122). ConClusions: Our 
findings indicate that adding sorafenib to a hypothetical health plan’s formulary 
has a manageable budget impact of $282,467, or a PMPM increase of $0.02, given 
the small RAI-r DTC population.
